A Study on the Application and Use of Artificial Intelligence to Support Drug Development

被引:51
|
作者
Lamberti, Mary Jo [1 ]
Wilkinson, Michael [1 ]
Donzanti, Bruce A. [2 ]
Wohlhieter, G. Erich [3 ]
Parikh, Sudip [4 ]
Wilkins, Robert G. [5 ]
Getz, Ken [1 ]
机构
[1] Tufts Univ, Sch Med, Tufts Ctr Study Drug Dev, Boston, MA 02111 USA
[2] Genentech Inc, Global Pharmacovigilance Innovat Policy, San Francisco, CA 94080 USA
[3] Amgen Inc, Digital Hlth & Innovat, Thousand Oaks, CA USA
[4] Drug Informat Assoc Amer, Washington, DC USA
[5] QPS Consulting LLC, Ashburn, VA USA
关键词
AI; artificial intelligence; drug development; machine learning; technology;
D O I
10.1016/j.clinthera.2019.05.018
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: The Tufts Center for the Study of Drug Development (CSDD) and the Drug Information Association (DIA) in collaboration with 8 pharmaceutical and biotechnology companies conducted a study examining the adoption and effect of artificial intelligence (AI), such as machine learning, on drug development. The study was conducted to clarify and understand AI adoption across the industry and to gather detailed insights into the spectrum of activities included in the definition of AI. The study investigated and identified analytical platforms and innovations across pharmaceutical and biotechnology companies currently being used or planned for in the future. Methods: A 2-part method was used that comprised in-depth interviews with AI industry experts and a global survey conducted across pharmaceutical and biotechnology organizations. Eleven in-depth interviews focused on use and implementation of AI across drug development. The survey assessed use of AI and included perceptions about current and future use. The survey also examined technology definitions, assessment of organizational and personal AI expertise, and use of partnerships. A total of 402 responses, including data from 217 unique organizations, were analyzed. Findings: Although 7 in 10 respondents reported using AI in some capacity, a wide range of use was reported by AI type. Patient selection and recruitment for clinical studies was the most commonly reported AI activity, with 34 respondents currently using AI for this activity. In addition, identification of medicinal products data gathering was the top activity being piloted or in the planning stages, reported by 49 respondents. The study also revealed that the most significant challenges to AI implementation included staff skills (55%), data structure (52%), and budgets (49%). Nearly 60% of respondents noted planned increases in staff within 1-2 years to support AI use or implementation. Implications: Despite the challenges to AI implementation, the survey revealed that most organizations use AI in some capacity and that it is important to the success of an organization's workforce. Many organizations reported expectations for increasing staff as implementation of AI expands. Further research should examine the changing development landscape as the role of AI evolves. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:1414 / 1426
页数:13
相关论文
共 50 条
  • [21] The Application of Artificial Intelligence in Ocean Development
    Yu, Yang
    Gu, LeiLei
    Wu, Xiangqi
    ENVIRONMENTAL ENGINEERING, PTS 1-4, 2014, 864-867 : 2116 - 2119
  • [22] The application of artificial intelligence to drug sensitivity prediction
    Li, Xutong
    Wu, Xiaolong
    Wan, Xiaozhe
    Zhong, Feisheng
    Cui, Chen
    Chen, Yingjia
    Chen, Lifan
    Chen, Kaixian
    Jiang, Hualiang
    Zheng, Mingyue
    CHINESE SCIENCE BULLETIN-CHINESE, 2020, 65 (32): : 3551 - 3561
  • [23] The use of Artificial Intelligence Algorithms in drug development and clinical trials: A scoping review
    Pontes, Camila de Brito
    Netto, Antonio Valerio
    INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS, 2025, 195
  • [24] Thinking on the Use of Artificial Intelligence in Drug Discovery
    Wang, Yuxi
    Hu, Zelin
    Chang, Junbiao
    Yu, Bin
    JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (05) : 4996 - 4999
  • [25] Artificial Intelligence in Accelerating Drug Discovery and Development
    Tripathi, Anushree
    Misra, Krishna
    Dhanuka, Richa
    Singh, Jyoti Prakash
    Recent Patents on Biotechnology, 2023, 17 (01) : 9 - 23
  • [26] Artificial Intelligence Might Streamline Drug Development
    Davidson, Robert
    US PHARMACIST, 2023, 48 (10) : 4 - 4
  • [27] Editorial: Artificial intelligence in drug discovery and development
    Wei, Leyi
    Zou, Quan
    Zeng, Xiangxiang
    METHODS, 2024, 226 : 133 - 137
  • [28] The Role of Artificial Intelligence in Drug Discovery and Development
    Ozaybi, Mazen Qassem Bohais
    Madkhali, Ahmed Nahari Mohammad
    Alhazmi, Mohammed Ali Mohammed
    Faqihi, Hesham Mohammad Ahmad
    Alanazi, Mshari Marzoq
    Siraj, Waheed Hadi Yahya
    Zalah, Ahmed Hussain Ahmed
    Khormi, Mohammed Mohsen Abdu
    Salem, Ali Mohammed Ahmed Al
    Mashragi, Talal Qasim Mosa
    Alotaibi, Ahmed Nawaf
    Naji, Ahmed Ali Mussa
    Bagal, Rehab Moaied Abdo
    Marwee, Hussain Ali Ahmed
    EGYPTIAN JOURNAL OF CHEMISTRY, 2024, 67 (13): : 1541 - 1547
  • [29] Impact of Artificial Intelligence on Drug Development and Delivery
    Aundhia, Chintan
    Parmar, Ghanshyam
    Talele, Chitrali
    Shah, Niyati
    Talele, Dipali
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2024,
  • [30] Applications of artificial intelligence to new drug development
    Moingeon, P.
    ANNALES PHARMACEUTIQUES FRANCAISES, 2021, 79 (05): : 566 - 571